[6-Chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H1-imidazo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-ethyl-amine | 444325-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [6-Chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H1-imidazo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-ethyl-amine
• 英文别名: N-((2-chloro-1-mesityl-6-(trifluoromethyl)-1H-imidazo[1,2-a]imidazol-5-yl)methyl)-N-(cyclopropylmethyl)ethanamine；N-[[2-chloro-6-(trifluoromethyl)-1-(2,4,6-trimethylphenyl)imidazo[1,2-a]imidazol-5-yl]methyl]-N-(cyclopropylmethyl)ethanamine
• CAS: 444325-09-1
• 化学式: C₂₂H₂₆ClF₃N₄
• 分子量: 438.923
• InChiKey: XULKXQDGWXRMRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-chloro-5-chloromethyl-6-trifluoromethyl-1-(2,4,6-trimethyl-phenyl)-1H-imidazo[1,2-a]imidazole 、 N-乙基环丙烷甲胺 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.25h， 生成 [6-Chloro-2-trifluoromethyl-7-(2,4,6-trimethyl-phenyl)-7H1-imidazo[1,2-a]imidazol-3-ylmethyl]-cyclopropylmethyl-ethyl-amine
  参考文献：
  名称：

  Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists

  摘要：

  A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF1R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discussed herein. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.094

文献信息

• Imidazolyl derivatives as corticotropin releasing factor inhibitors
  申请人：——

  公开号：US20020183375A1

  公开（公告）日：2002-12-05

  The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及一种新型杂环拮抗剂，其化学式为(I)，以及包含所述拮抗剂的药物组合物，用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可以通过拮抗CRF-1受体来治疗的病症。
• [EN] IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS<br/>[FR] DERIVES IMIDAZOLYLES COMME INHIBITEURS DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002058704A1

  公开（公告）日：2002-08-01

  The present invention relates to novel heterocyclic antagonists of Formula I and pharmaceutical compositions comprising said antagonists of the coticotropin releasing factor receptor ('CRF receptor') (formula), useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及公式I的新型杂环拮抗剂和包含所述拮抗剂的药物组合物，该药物组合物对促肾上腺皮质激素释放因子受体（'CRF受体'）具有拮抗作用，用于治疗抑郁症、焦虑症、情感障碍、饮食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状和其他可以通过CRF-1受体的拮抗作用治疗的疾病。
• IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING FACTOR INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1359916A1

  公开（公告）日：2003-11-12
• EP1359916A4
  申请人：——

  公开号：EP1359916A4

  公开（公告）日：2004-04-07
• US6888004B2
  申请人：——

  公开号：US6888004B2

  公开（公告）日：2005-05-03